Pancreatic Cancer Research

ResearcherPennsylvania State UniversityActive in the last 2 years

Jill Palmer Smith

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0835-4802; OpenAlex author ID A5025034153. Sources: OpenAlex.

Their work

Papers
27 (first author 1, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 3 papers · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 4 papers · 2019: 3 papers · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 27

  1. Probiotics Mitigate Cholesterol-induced Gut Dysbiosis and Promotion of Pancreatic Cancer Progression. First author DOI 10.1016/j.jcmgh.2026.101724↗
  2. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  3. Target-Specific Locked Nucleic Acid Gapmer Decreases Growth and Metastases of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-24-1059↗
  4. Downregulation of the CCK-B Receptor in Pancreatic Stellate Cells Blocks Molecular Proliferative Pathways and Increases Apoptosis to Decrease Pancreatic Cancer… Last author DOI 10.3390/ijms262311699↗
  5. Does Chronic Use of High Dose Proton Pump Inhibitors Increase Risk for Pancreatic Cancer? Last author DOI 10.1097/mpa.0000000000002145↗
  6. A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Co-author DOI 10.1016/j.ajhg.2021.09.002↗
  7. Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment. Last author DOI 10.3390/cancers13194949↗
  8. TGFβ Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGFβ Induced EMT in PDAC. Co-author DOI 10.3390/cancers13246204↗
  9. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  10. Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment. Last author DOI 10.1007/s00262-019-02398-6↗
  11. ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression. Last author DOI 10.1007/s00262-019-02422-9↗
  12. Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases. Last author DOI 10.1152/ajpgi.00145.2019↗
  13. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Co-author DOI 10.1007/s00262-017-2077-9↗
  14. Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer. Last author DOI 10.1016/j.jcmgh.2018.02.013↗
  15. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  16. Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptor. Last author DOI 10.1152/ajpgi.00123.2018↗
  17. Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic ca… Co-author DOI 10.1016/j.nano.2017.06.017↗
  18. A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1089/nat.2016.0621↗
  19. Functional characterization of a chr13q22.1 pancreatic cancer risk locus reveals long-range interaction and allele-specific effects on DIS3 expression. Co-author DOI 10.1093/hmg/ddw300↗
  20. The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies. Co-author DOI 10.7150/ijbs.14952↗
  21. Distribution of cholecystokinin-B receptor genotype between patients with pancreatic cancer and controls and its impact on survival. Co-author DOI 10.1097/mpa.0000000000000263↗
  22. Cholecystokinin mediates progression and metastasis of pancreatic cancer associated with dietary fat. Last author DOI 10.1007/s10620-014-3201-8↗
  23. Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice. Co-author DOI 10.1097/mpa.0000000000000194↗
  24. Cholecystokinin and pancreatic cancer: the chicken or the egg? Co-author DOI 10.1152/ajpgi.00301.2013↗
  25. Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Co-author DOI 10.1097/mpa.0b013e3182a9ad9d↗
  26. Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis. Last author DOI 10.1152/ajpgi.00460.2011↗
  27. A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer. Co-author DOI 10.4161/cbt.13.3.18698↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jack C. Drda · 1 shared paper, 2026 · strength 0.63
  2. Sandeep Nadella · 5 shared papers, 2018–2022 · strength 0.49
  3. Julian Burks · 4 shared papers, 2018–2019 · strength 0.39
  4. Gail L. Matters · 8 shared papers, 2012–2017 · strength 0.37
  5. Stęphan T. Stern · 2 shared papers, 2018–2025 · strength 0.33
  6. Mariaelena Pierobon · 1 shared paper, 2025 · strength 0.27
  7. Miranda Ortega · 1 shared paper, 2025 · strength 0.27
  8. Amrita K. Cheema · 2 shared papers, 2021 · strength 0.23
  9. Nicholas Osborne · 2 shared papers, 2019 · strength 0.18
  10. Mark A. Kester · 3 shared papers, 2014–2017 · strength 0.16
  11. Matthew Huber · 1 shared paper, 2022 · strength 0.14
  12. Zoe X. Malchiodi · 1 shared paper, 2021 · strength 0.13
  13. Benjamin Adam Weinberg · 1 shared paper, 2021 · strength 0.13
  14. Gary A. Clawson · 2 shared papers, 2017 · strength 0.12
  15. James H. Adair · 2 shared papers, 2017 · strength 0.12
  16. Thomas Abraham · 2 shared papers, 2017 · strength 0.12
  17. Samuel S. Linton · 2 shared papers, 2017 · strength 0.12
  18. Welley Siu Loc · 2 shared papers, 2017 · strength 0.12
  19. Louis M. Weiner · 1 shared paper, 2018 · strength 0.11
  20. Baldev B. Singh · 1 shared paper, 2021 · strength 0.10
  21. Shreyans Kumar Jain · 1 shared paper, 2021 · strength 0.10
  22. Partha P. Banerjee · 1 shared paper, 2021 · strength 0.10
  23. Charles P. Hinzman · 1 shared paper, 2021 · strength 0.10
  24. Meena U. Rajagopal · 1 shared paper, 2021 · strength 0.10
  25. Keith Robert Unger · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.